-
Enrollment Complete in Phase 2 Trial Testing Temelimab
The study of temelimab has enrolled 42 people with relapsing MS whose disability progressed in the absence of relapses after treatment with rituximab. Click here to learn more.
Are you following this study? What do you think of the findings so far?
Sorry, there were no replies found.
Log in to reply.